SEK 42.2
(2.93%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 229.42 Million EUR | 18.27% |
2022 | 193.99 Million EUR | 57.91% |
2021 | 122.84 Million EUR | 28.62% |
2020 | 95.51 Million EUR | 518.95% |
2019 | 15.43 Million EUR | 235.55% |
2018 | 4.59 Million EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 63.24 Million EUR | 8.87% |
2024 Q2 | 64.16 Million EUR | 1.46% |
2024 Q3 | 61.21 Million EUR | -4.6% |
2023 Q4 | 58.09 Million EUR | 7.79% |
2023 Q2 | 56.55 Million EUR | -7.1% |
2023 Q3 | 53.89 Million EUR | -4.71% |
2023 Q1 | 60.88 Million EUR | 17.31% |
2023 FY | 229.42 Million EUR | 18.27% |
2022 Q4 | 51.89 Million EUR | 6.53% |
2022 FY | 193.99 Million EUR | 57.91% |
2022 Q3 | 48.71 Million EUR | 3.8% |
2022 Q2 | 46.93 Million EUR | 1.07% |
2022 Q1 | 46.44 Million EUR | 35.07% |
2021 Q2 | 27.82 Million EUR | -12.44% |
2021 FY | 122.84 Million EUR | 28.62% |
2021 Q4 | 34.38 Million EUR | 18.84% |
2021 Q3 | 28.93 Million EUR | 3.98% |
2021 Q1 | 31.77 Million EUR | -52.77% |
2020 Q1 | 7.27 Million EUR | 0.0% |
2020 Q3 | 12.91 Million EUR | 60.56% |
2020 Q2 | 8.04 Million EUR | 10.52% |
2020 Q4 | 67.27 Million EUR | 420.83% |
2020 FY | 95.51 Million EUR | 518.95% |
2019 FY | 15.43 Million EUR | 235.55% |
2018 FY | 4.59 Million EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AroCell AB (publ) | -2.1 Million SEK | 11014.653% |
Devyser Diagnostics AB (publ) | 148.1 Million SEK | -54.913% |
Immunovia AB (publ) | -5.1 Million SEK | 4592.383% |
Prostatype Genomics AB (publ) | -18.09 Million SEK | 1368.248% |
SenzaGen AB | 34.93 Million SEK | -556.779% |
Spermosens AB | -169 Thousand SEK | 135855.03% |